- Updates
-
`
1. Memorandum of Understanding:
Regional Antituberculous Hospital in Ukraine has committed to funding and conducting clinical studies of Enercel for Tuberculosis, Multidrug-resistant Tuberculosis and Lung Cancer
Abstract:
AIMS: Amyotrophic Lateral Sclerosis (ALS) is a progressive, uniformly fatal, degenerative disorder of upper and motor neurons without any current effective treatment. We report on two case-studies of patients with ALS treated with 4 weeks of Acupuncture injection point therapy using Enercel®.RESULTS: Two patients were given Enercel® Plus IM 0.25 to 0.5 cc at specific Acupuncture points 5 days per week for 4 weeks. Patient #1 presented with flaccid paralysis of all 4 extremities and impaired speech and swallowing. By week 4, she had significant improvement in motor strength of all 4 extremities, R > L, and improvements in speech and swallowing. Patient #2 had significantly impaired speech and mild motor loss in both upper extremities and left leg. After 4 weeks, his voice had significantly improved to the point that his speech was understandable and his motor function had returned to normal.
CONCLUSIONS: Thus, two patients with ALS improved after 4 weeks of Enercel® Acupoint injection therapy. This preliminary data merits further study and confirmation.
3. Potential Mechanism of Action of
Homeopathic Formulations: Based upon recent studies showing energetic activity of highly diluted biological compounds.4. Combination Homeopathy, Products in the Retail Setting
Lesson supported by an educational grant from Hyland’s
5. Stealth-Adapted Viruses and Alternative Cellular Energy
W. John Martin, MD
6. Enercel products have been officially registered by Government Regulatory Agencies in Central American, Eastern European and Southeast Asian countries
